Finnish innovation enables heart disease detection via smartphone

CardioSignal’s technology harnesses gyroscope and accelerometer motion data from smartphones to measure specific rotational movements of the heart. This data can then be used to accurately detect abnormal heart function.

The user merely lies down and places their smartphone on their chest for one minute to facilitate the check via the CardioSignal application.

“CardioSignal has the potential to meaningfully impact heart disease on a global basis,” said David J. Kim, managing director of DigiTx Partners, which led the Series A funding round. “Besides the ability to detect various heart diseases, which continue to be one of the common causes of death, CardioSignal has lowered the barrier to the adoption of its technology by making it readily available to all individuals who have smartphones.”

The Series A investment will fund additional clinical validation and broader commercial expansion of the earlier detection and and remote monitoring solution for primary care doctors and their patients.

“Currently, primary care has very limited tools to detect heart diseases, like heart failure patients who are often already experiencing symptoms,” affirmed cardiologist Dr. Juuso Blomster, founder and CEO of CardioSignal.

The company is backed by more than 50 patents covering its method and clinical algorithms, which in turn are based on gyrocardiography. These have been researched and documented in more than 20 peer-reviewed scientific publications.

The CardioSignal application is already available in 15 countries. The company is headquartered in Turku, Finland, with a subsidiary in Palo Aalto, California. Sandwater and existing investor Maki.vc also participated in the round, bringing the total amount of funding raised to date to 23 million US dollars